title: Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma.
abstract: BACKGROUND
  The aim of this review was to discuss the role of altered fractionation and adjuvant chemotherapy for patients treated with definitive radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  This review explores the pertinent literature and discusses the optimal management of previously untreated patients with stage III-stage IVA and/or -B HNSCCs.
  
  
  RESULTS
  Depending on the schedule, altered fractionation improves locoregional control and survival. Both hyperfractionation and concomitant boost RT improve locoregional control and are associated with improved overall survival (OS). Adjuvant chemotherapy improves OS; the greatest impact is observed after concomitant versus induction or maintenance chemotherapy. Monochemotherapy appears to be equivalent to polychemotherapy. Drugs associated with the greatest survival benefit include fluorouracil and cisplatin. Intraarterial chemotherapy offers no advantage over intravenous chemotherapy. Concomitant cetuximab and RT results in improved outcomes similar to those observed after concomitant cisplatin-based chemotherapy and RT.
  
  
  CONCLUSIONS
  Altered fractionation and/or concomitant chemotherapy result in improved outcomes compared with conventionally fractionated definitive RT alone for stage III-stage IV HNSCC. The optimal combination of RT fractionation and chemotherapy remains unclear.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA. mendwm@shands.ufl.edu
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: Charles E
authors.initials: CE
authors.lastname: Riggs
authors.forename: Mikhail
authors.initials: M
authors.lastname: Vaysberg
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Amdur
authors.forename: John W
authors.initials: JW
authors.lastname: Werning
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D019583:Dose Fractionation, Radiation; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents